International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 147-152
PLASMA TISSUE FACTOR LEVELS IN PATIENTS WITH COLON CANCER RECEIVING INFUSIONAL 5-FLUOROURACIL CHEMOTHERAPY
İLHAN ÖZTOP1, HALİL ATEŞ1, AHMET ALACACIOĞLU1, ARZU YAREN1, OKTAY TARHAN1, MEHMET ALAKAVUKLAR1, UĞUR YILMAZ1
Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, İZMİR
Keywords: infusional 5-fluorouracil, vascular complication, tissue factor
In recent years, the vascular toxicity of cancer chemotherapy drugs has become more widely subject of interest. Although spesific vascular complications have been described following the administration of particular chemotherapeutic agents, the role 5-FU in the development of vascular complications in cancer patients remains largely speculative. In this study, ten patients with colon cancer receiving infusional 5-FU bimonthly were studied for plasma tissue factor levels by the ELISA method, and test results were compared with the results obtained at baseline period (before 5-FU administration). All patients were diagnosed as stage II or III colon cancer. There was a mild increase of plasma tissue factor levels during the infusional 5-FU chemotherapy (treatment group) compared with baseline levels (control group), but this increase was not statistically significant. Mean plasma TF level of the control group was 36.2±24.2 pg/ml (range 10.3 to 90.5) and treatment group was 49.1±40.5 pg/ml (range 5.4 to 134.1). No thrombotic complications were observed in whole group. Plasma tissue factor may have a role in the development of vascular complications in patients who are receiving infusional 5-FU chemotherapy.
İLHAN ÖZTOP1, HALİL ATEŞ1, AHMET ALACACIOĞLU1, ARZU YAREN1, OKTAY TARHAN1, MEHMET ALAKAVUKLAR1, UĞUR YILMAZ1
Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, İZMİR
Keywords: infusional 5-fluorouracil, vascular complication, tissue factor
In recent years, the vascular toxicity of cancer chemotherapy drugs has become more widely subject of interest. Although spesific vascular complications have been described following the administration of particular chemotherapeutic agents, the role 5-FU in the development of vascular complications in cancer patients remains largely speculative. In this study, ten patients with colon cancer receiving infusional 5-FU bimonthly were studied for plasma tissue factor levels by the ELISA method, and test results were compared with the results obtained at baseline period (before 5-FU administration). All patients were diagnosed as stage II or III colon cancer. There was a mild increase of plasma tissue factor levels during the infusional 5-FU chemotherapy (treatment group) compared with baseline levels (control group), but this increase was not statistically significant. Mean plasma TF level of the control group was 36.2±24.2 pg/ml (range 10.3 to 90.5) and treatment group was 49.1±40.5 pg/ml (range 5.4 to 134.1). No thrombotic complications were observed in whole group. Plasma tissue factor may have a role in the development of vascular complications in patients who are receiving infusional 5-FU chemotherapy.